Antibody discovery platforms
These companies discover or engineer antibodies and license them to drug-making partners.
+59.4%
over 6 months · S&P 500 +2.6%
Key indicators
Health
49 / 100
Fragile
Solid
Up over 1 year
6 of 9
Volatility
86%
Calm
Choppy
Profitability
−219%
Low
High
Health and price: against the other tags.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
The 11 companies
XNCR
+230.6%
GENB
−24.6%
ABSI
+64.7%
OABI
+125.2%
ATTO
Size: weight in the tag. Color: move over the period.
See all companies
See all companies
X
Xencor
XNCR
34.3%
+230.6%
G
Generate Biomedicines
GENB
21.8%
−24.6%
A
Absci
ABSI
18.0%
+64.7%
O
OmniAb
OABI
9.2%
+125.2%
A
Attovia Therapeutics
ATTO
9.0%
C
CytomX Therapeutics
CTMX
5.7%
−43.5%
S
Sutro Biopharma
STRO
2.0%
−74.8%
B
BioAtla
BCAB
<0.1%
−59.4%
A
AbCellera Biologics
ABCL
+180.9%
A
Adagene
ADAG
−51.1%
G
Genmab
GMAB
+93.6%